
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd has positioned itself strongly within the pharmaco-epigenetics space through collaborations and strategic partnerships, which are likely to enhance revenue growth and increase the adoption of its biomarker technology. The validation of the Nu.Q Lung Cancer Test represents a pivotal opportunity, potentially de-risking the technology and making it more appealing for strategic partnerships with major diagnostic and pharmaceutical players. Additionally, the successful rollout of its automated systems in Japan has already seen adoption by over 1,000 veterinary hospitals, reflecting robust market interest and the potential to significantly boost VolitionRX's revenue from its diagnostic offerings.
Bears say
VolitionRX Ltd faces a negative outlook due to the ongoing challenges in its development of effective diagnostic tests, particularly highlighted by the issues surrounding high false-positive rates in its current study related to pulmonary nodules. These challenges jeopardize the company's ability to deliver reliable and cost-effective solutions, potentially impacting market acceptance and revenue generation. Additionally, the reliance on its Nucleosomics platform amidst significant competition in the diagnostics space raises concerns about the company's long-term financial viability and growth prospects.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares